Multifactorial interaction among lipoproteins, vascular wall cells, and inflammatory mediators has been recognized as the basis of atherogenesis. In the arterial wall high-density lipoprotein (HDL) and human secretory phospholipase A 2 (sPLA 2 ) colocalize with vascular smooth muscle cells and concentrate in the atherosclerotic lesions. It has been shown that gr IIA sPLA 2 hydrolyzes lipoproteins, altering their structure and releasing active agents such as lyso-phosphatidylcholine (PtdCho) and free fatty acids. We investigated the impact of normal HDL 3 (NHDL 3 ), acute phase HDL 3 (APHDL 3 ), and low-density lipoprotein (LDL), both unhydrolyzed and sPLA 2 -hydrolyzed, and some products of hydrolysis, such as lyso-PtdCho, oleic and linoleic acid, on [
A therosclerosis is the end stage of a complex interaction of several types of vascular wall resident and infiltrating cells, lipoproteins, and a variety of inflammatory mediators (Daugherty, 1997; Libby et al, 1997; Steinberg and Witztum, 1990) . Recently, substantial evidence has accumulated indicating that proinflammatory and immunologic factors play an important role in atherogenesis (Hajjar and Pomerantz 1992; Hansson et al, 1989; Nilsson, 1993; Wick et al, 1995 Wick et al, , 1997 . It was found that acute phase markedly influences the structure of lipoproteins (Malle et al, 1993; Pruzanski et al, 1998 Pruzanski et al, , 2000 and their functions (Kisilevsky and Subrahmanyan, 1992; Shephard et al, 1987; Van Lenten et al, 1995) . In acute phase (Baumann and Gauldie, 1994; Steel and Whitehead, 1994) and in some chronic inflammatory diseases in which prolonged overexpression of acute phase reactants takes place (de Beer et al, 1982; Pruzanski et al, 1993; Vadas et al, 1993) , serum amyloid A apolipoprotein (SAA) binds avidly to high-density lipoprotein (HDL), converting it into acute-phase (APHDL) (Malle et al, 1993; Van Lenten et al, 1995) . While acquiring SAA, APHDL loses in part apo AI and apo AII, and some enzymes such as paroxonase and platelet activating factor (PAF)-acetylhydrolase (Van Lenten et al, 1995) . Alterations in the lipid content of APHDL also occur (Pruzanski et al, 2000) . APHDL is unable to protect against oxidation of low-density lipoprotein (LDL) and becomes proinflammatory (Van Lenten et al, 1995) .
We reported that another acute phase reactant, human proinflammatory gr IIA secretory phospholipase A 2 (sPLA 2 ) is almost invariably co-overexpressed with SAA . SAA was found to be a cofactor of sPLA 2 , markedly enhancing its hydrolytic activity (Pruzanski et al, 1995) . In turn, sPLA 2 hydrolyzes HDL, APHDL, and LDL, releasing lyso-compounds and free fatty acids (Pruzanski et al, 1998) , which per se can modify the activity of and may be toxic to a variety of cells (Fang et al, 1997; Kume et al, 1992; Locher et al, 1992; Kaneko et al, 1996; Quinn et al, 1988; Yagi et al, 1996; Yamakawa et al, 1998) . APHDL is hydrolyzed by sPLA 2 faster than normal (N)HDL (Pruzanski et al, 1998) .
It has been shown that in atherosclerosis, lipoproteins and sPLA 2 are colocalized in the vascular wall, mainly in the domain of the smooth muscle cells (Hurt-Camejo et al, 1997; Robenek and Severs, 1993; Romano et al, 1998; Sartipy et al, 1998) . Thus, it is of significant interest that in some diseases such as systemic lupus erythematosus, in which SAA and sPLA 2 are co-overexpressed for long periods (de Beer et al, 1982; Pruzanski et al, 1994) , accelerated atherosclerosis takes place (Bruce et al, 1998; Urowitz and Gladman, 1999) . Furthermore, it has been shown that transgenic mice that overexpress human sPLA 2 develop accelerated atherosclerosis . It has been shown that one of the important initial steps leading to atherosclerotic changes is proliferation and subsequent migration of the vascular smooth muscle cells (Raines and Ross, 1993; Rosenberg and Simons, 1996; Stein and Stein, 1995) . Thus, it was important to investigate whether hydrolytic activity of human sPLA 2 , used in concentrations that occur in vivo, especially in the vascular wall, has an impact on lipoprotein-induced mitogenic effect in human vascular smooth muscle cells (VSMC) and whether APHDL enhances it more actively than normal HDL. Herein, we report that HDL 3 , APHDL 3 , and LDL hydrolyzed by gr IIA sPLA 2 markedly enhanced thymidine incorporation and proliferation of human VSMC. Furthermore, known products of sPLA 2 -induced hydrolysis of lipoproteins, such as lyso-phosphatidylcholine (PtdCho), and oleic and linoleic acid also exerted a marked mitogenic effect. Thus, sPLA 2 may be considered as a novel proatherogenic enzyme, which may be especially important in conditions in which its prolonged overexpression takes place.
Results

Basic Conditions of Human VSMC Cultures
Human VSMC were cultured with various concentrations of fatty acid free (FAF) BSA. When final BSA concentration was 0.1%, the mean [ 3 H] thymidine incorporation was 10,865 Ϯ 2,541 cpm (SD) per well (n ϭ 12, in triplicate). The addition of 0.1% FAF BSA resulted in an insignificant change: 11,800 Ϯ 5,973 cpm (SD) per well (n ϭ 10, in triplicate). However, the addition of 10% FCS induced a marked increase in thymidine incorporation up to 30,947 Ϯ 19,813 cpm (SD) per well (n ϭ 12, in triplicate) or 607 Ϯ 182% of controls (p Ͻ 0.01). The final concentration of FAF BSA in the media assumed more importance when the impact of normal HDL 3 (NHDL 3 ) on mitogenic activity was tested. Over the range of concentrations of 20 to 200 g/ml of NHDL 3 (n ϭ 7), lower concentrations of BSA invariably resulted in a stronger induction of mitogenic activity by mitogens, increasing it up to 3.5-fold. Thus, the experiments were performed with low BSA concentrations. At the end of the culturing period before and after the tested agents were added, quiescent VSMC were viable Ն 95%, and maintained the original shape and size. There was no increase in LDH in the supernatant.
Influence of NHDL 3 on Human VSMC
The impact of NHDL 3 (n ϭ 6) on mitogenic activity of human VSCM was tested over the range of 20 to 400 g/ml and incubation times of 1 hour to 24 hours. Invariably, NHDL 3 markedly increased thymidine incorporation. Representative results are shown in Figure 1 and Table 1 . The increase over controls was dose-dependent and varied from 124 Ϯ 29% at 20 g/ml to 222 Ϯ 36% at 100 g/ml (p Ͻ 0.001). The incubation of VSMC with NHDL 3 for 4 hours was usually sufficient to reach the maximum effect; however, the increase in mitogenic activity of 8% to 18% over the controls was already seen after 1 hour of incubation.
Influence of APHDL 3 on Human VSMC
APHDL 3 (n ϭ 6) markedly enhanced mitogenic activity of VSMC in a dose-and time-dependent manner. Invariably APHDL 3 was more active than NHDL 3 (Fig.  1 , Table 1 ). Equal mitogenic effect of APHDL 3 was usually achieved by a half dose of NHDL 3 . After 4 hours of incubation, 25 g/ml APHDL 3 enhanced thymidine incorporation equally to 50 g/ml NHDL 3 (p ϭ 0.003).
Influence of NHDL 3 Preincubated with SAA on Human VSMC
Preincubation of NHDL 3 with SAA (n ϭ 3) led to a significant enhancement of [ 3 H] thymidine incorporation into the human VSMC compared with NHDL 3 alone (Fig. 2) . As little as 5 g/ml SAA preincubated with 40 g/ml NHDL 3 for 4 hours was sufficient to increase the incorporation by 25%.
Influence of NHDL 3 Hydrolyzed by sPLA 2 on Human VSMC NHDL 3 hydrolyzed by sPLA 2 invariably increased thymidine incorporation in human VSMC much more than nonhydrolyzed NHDL 3 (n ϭ 12). The increase in mito-
Figure 1.
Induction of the mitogenic activity of human vascular smooth muscle cells (VSMC) by normal high-density lipoprotein (NHDL 3 ) (Ⅵ) and acute-phase HDL (APHDL 3 ) (⅙). Example experiment of six experiments performed in triplicate giving comparable results.
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genic activity was related to the duration of the preincubation of NHDL 3 with sPLA 2 and to the concentration of sPLA 2 (Fig. 3, Table 1 ). The longer the incubation time, the lower the concentration of sPLA 2 required to induce a significant mitogenic effect. For example, incubation of 50 g/ml NHDL 3 with 100 ng/ml sPLA 2 for 24 hours resulted in thymidine uptake of 41,285 Ϯ 791 cpm/well, whereas a 48-hour preincubation with only 20 ng/ml sPLA 2 enhanced incorporation to 45,955 Ϯ 6,537 cpm/well. sPLA 2 per se, tested at the range of 1 to 100 ng/ml, had no effect on mitogenic activity. [
3 H] thymidine incorporation, testing the effect of gr IIA sPLA 2 (100 ng/ml) on VSMC exposed to the enzyme for 24 hours, was 12,093 Ϯ 158 (SEM) cpm/well as compared with the controls of 12,171 Ϯ 178 (SEM) cpm/well (n ϭ 22). There was no evidence for hydrolysis of the cellular membrane of VSMC by extrinsic sPLA 2 . Cultured VSMC exposed or not exposed to lipoproteins did not release sPLA 2 to the medium (n ϭ 6). There was correlation between the incorporation of radiolabeled thymidine into the VSMC and the number of proliferating cells. As expected, HDL 3 alone induced both; however, HDL 3 hydrolyzed by sPLA 2 further increased both variables ( Table 2) .
Influence of APHDL 3 Hydrolyzed by sPLA 2 on Human VSMC
Hydrolysis of APHDL 3 by sPLA 2 enhanced the effect on mitogenic activity of human VSMC (n ϭ 12) proportionately to the time of incubation and the concentration of sPLA 2 (Fig. 4 , Table 1 ). The relative effect of sPLA 2 on the induction of mitogenic activity by APHDL 3 was less than that of NHDL 3 , because APHDL 3 per se was invariably enhancing thymidine The effect of serum amyloid A apolipoprotein (SAA) on the mitogenic activity of human VSMC induced by NHDL 3 . HDL 3 50 g/ml, SAA 10 and 25 g/ml. SAA vs control, not significant; HDL 3 vs control, p Ͻ 0.01; HDL 3 ϩ SAA 10 or 25 mg/ml vs control, p Ͻ 0.005; HDL 3 ϩ SAA 25 g/ml vs HDL 3 , p Ͻ 0.01. This experiment represents three experiments (in triplicate) that gave comparable results.
Figure 3.
Induction of mitogenic activity in human VSMC by NHDL 3 hydrolyzed by gr IIA secretory phospholipase A 2 (sPLA 2 ). Example of 12 experiments in triplicate. } NHDL 3 alone 50 g/ml; ⅙ NHDL 3 ϩ sPLA 2 2 ng/ml; Ⅵ NHDL 3 ϩ sPLA 2 10 ng/ml; ' NHDL 3 ϩ sPLA 2 20 ng/ml. At 48 hours, NHDL 3 vs NHDL 3 ϩ sPLA 2 10 ng/ml, p Ͻ 0.05. At 48 hours, HDL 3 vs HDL 3 ϩ sPLA 2 20 ng/ml, p Ͻ 0.01. The sPLA 2 range of 2 to 20 ng/ml is equivalent to 80 to 800 U/ml. Such concentrations are similar to those in human serum and are observed in arterial atherosclerotic areas. incorporation much more than NHDL 3 . Thus, additional enhancement by APHDL 3 hydrolyzed by sPLA 2 was less but clearly evident (Fig. 4 , Table 1 ). APHDL 3 per se, especially hydrolyzed by sPLA 2 , enhanced proliferation of the VSMC significantly more than HDL 3 and LDL (Table 2) .
Influence of LDL Unhydrolyzed and sPLA 2 -Hydrolyzed on Human VSMC
LDL added to the cultured VSMC markedly enhanced mitogenic activity (n ϭ 3, in triplicate). LDL per se enhanced mitogenic activity more than NHDL 3 or APHDL 3 (Table 1) . LDL hydrolyzed by sPLA 2 also enhanced mitogenic activity more than identically treated NHDL 3 or APHDL 3 (Table 1) . LDL alone and LDL hydrolyzed by sPLA 2 enhanced proliferation of VSMC significantly more than HDL 3 (Table 2) .
Influence of Lyso-PtdCho, and Linoleic and Oleic Acids on Human VSMC
Lyso-PtdCho was tested at the concentration range of 10 to50 M. Concentrations above 30 M were toxic to the cells as tested by the number of cells and LDH in the supernatant. Lyso-PtdCho (20 M, n ϭ 5), enhanced thymidine incorporation up to 245 Ϯ 42% of the control, whereas dp PtdCho (10 to 50 M) had no effect on mitogenic activity of human VSMC. Doseresponse of linoleic and oleic acids were tested in the range of 5 to 50 M. The optimal concentrations of both fatty acids to increase [ 3 H] thymidine incorporation were 10 to 20 M. Concentrations of linoleic acid above 20 M and of oleic acid above 30 M were toxic to the cells. These were, therefore, the maximum concentrations used (Table 3 ). Linoleic and oleic acids markedly enhanced mitogenic activity of human VSMC, and combinations of lyso-PtdCho with either linoleic or oleic acid were invariably more active than each agent tested separately (Table 3) . When NHDL 3 (50 g/ml) was preincubated for 4 hours with lysoPtdCho (20 M), oleic acid (20 M), or linoleic acid (20 M), and then the mixture was added to the culture of VSMC, there was a marked increase in mitogenic activity of 183%, 239%, and 191%, respectively, compared with NHDL 3 alone.
Influence of grIIA sPLA 2 on Human VSMC
To rule out the possibility that sPLA 2 per se may release phospholipids from the cell membrane, VSMC were incubated for 24 hours with sPLA 2 , 1 g/ml. The supernatant was tested for the presence of PtdCho, PtdEtn, SM, lyso-PtdCho and fatty acids, palmitic, stearic, linoleic, oleic, arachidonic, and others as described (Pruzanski et al, 2000) . The supernatants from the cells exposed to sPLA 2 contained only traces of PtdCho and SM identical to those in the controls. Washed and sonicated cells showed readily detectable amounts of PtdCho, with smaller amounts of PtdEt and SM. There was almost no lyso-PtdCho.
Discussion
The protective role of HDL in the atherosclerotic process is related, in part, to the prevention of the generation of oxidized LDL Steinberg and Witztum 1990) . However, investigation of the enzymes linked to HDL, such as lecithin: cholesterol acyl transferase, paraoxonase (PON), PAFacetylhydrolase (PAF-AH), and others (Navab et al, 1998; Tall, 1990) , has indicated much more complex functional roles of HDL (Navab et al, 1998) . It was stated that to function normally, HDL has to maintain equilibrium between its apolipoproteins and enzymatic content. For example, in transgenic mice, HDL 
Figure 4.
Induction of mitogenic activity in human VSMC by APHDL 3 hydrolyzed by gr IIA sPLA 2 . Ⅵ APHDL 3 alone; ⅙ APHDL 3 hydrolyzed by sPLA 2 (100 ng/ml). Preincubation of APHDL 3 with sPLA 2 , 4 hours. The differences at all three concentrations, p Ͻ 0.01.
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overexpressing apo A II has a lower content of PON, is unable to protect against oxidation of LDL, and induces monocyte transmigration (Castellani et al, 1997) .
In acute phase, when SAA is replacing, in part, apo A I and apo A II, HDL is losing PON and PAF-AH, and is unable to maintain its protective activity (Van Lenten et al, 1995) . The addition of external PON to such HDL reinstates its normal function (Van Lenten et al, 1995; Aviram et al, 1998) . Because a substantial part of apo A-I is lost during conversion of HDL into APHDL, and because apo A I contains the major part of lecithin: cholesterol acyl transferase, this enzyme activity is also lost in part during conversion (Van Lenten et al, 1995) . We recently reported that acute phase HDL also has a substantially different lipid structure from normal HDL (Pruzanski et al, 2000) .
Several other functions of HDL have also been described, such as the inhibition of PAF synthesis in stimulated endothelial cells, presumably by inhibiting the activation of acetyltransferase (Sugatani et al, 1996) . HDL induced the synthesis of prostaglandin E 2 (PGE 2 ) in VSMC (Pomerantz et al, 1984) and the activators of PLA 2 were additive or synergistic with HDL in the induction of PGE 2 . Because it was reported that PGE 2 inhibits VSMC proliferation (Hajjar and Pomerantz, 1992) , these results could imply that PLA 2 inhibits the proliferative activity of HDL. But our study definitely shows that hydrolysis of NHDL 3 by sPLA 2 markedly enhances mitogenic activity of VSMC. Therefore, the putative induction of PGE 2 by HDL is either inhibited by the hydrolytic process or the protective activity of PGE 2 is counteracted by the products of hydrolysis, or both.
Physiologically VSMC are not exposed to the serum, that is to the circulating HDL. It was found, however, that HDL localizes in the arterial wall in the cellular compartment and along with LDL is internalized by the macrophages and by VSMC, especially in the atherosclerotic plaques (Robenek and Severs, 1993) . Since sPLA 2 co-localizes in the same areas (Hurt-Camejo et al, 1997; Romano et al, 1998; Sartipy et al, 1998) , it most probably is capable of interacting with lipoproteins in situ.
Recently, attention has been directed to the alterations of normal HDL induced by acute phase reactants (Malle et al, 1993; Pruzanski et al, 1998) . In acute phase, SAA may increase 1,000-fold and binds avidly to HDL, partly displacing apo A I and apo A II (Malle et al, 1993) . SAA may be overexpressed for long periods in some chronic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (de Beer et al, 1982) . SAA converts HDL into APHDL reducing its protective function (Malle et al, 1993; Van Lenten et al; . During inflammation, APHDL 3 is cleared more rapidly from the circulation (Malle et al, 1993) . Its affinity to hepatocytes declines and the affinity to macrophages increases as compared with HDL (Kisilevsky and Subrahmanyan, 1992). APHDL 3 was found to be degraded 5 to 10 times faster during incubation with neutrophils or neutrophil-conditioned medium (Shephard et al, 1987) .
We have reported that another acute phase reactant, human gr IIA sPLA 2 , hydrolyzes NHDL and APHDL (Pruzanski et al, 1998) , thus linking this proinflammatory enzyme to the atherogenic process. APHDL was hydrolyzed by sPLA 2 faster and more extensively than NHDL (Pruzanski et al, 1998) . Conversely, SAA and APHDL were found to increase the hydrolytic activity of sPLA 2 , implying that SAA may serve as a cofactor of sPLA 2 (Pruzanski et al, 1995) . sPLA 2 is produced by a variety of cells and can increase 1,000-fold or more in acute inflammatory processes . Prolonged overexpression of sPLA 2 was found in several diseases such as RA (Lin et al, 1996) and SLE (Pruzanski et al, 1994) , that is in the same conditions in which overexpression of SAA takes place (Steel and Whitehead, 1994) . In RA the concentrations of circulating sPLA 2 may reach values above 400 ng/ml (Lin et al, 1996) , whereas in SLE concentrations above 300 ng/ml were found (Pruzanski et al, 1994) . Its induction is controlled by the same agents that induce SAA, such as cytokines, endotoxin, and others (Vadas et al, Incubation time of VSMC with various agents, 4 hours. The difference between lyso PtdCho ϩ linoleic acid and lyso PtdCho alone, p ϭ .011, and with linoleic acid alone, p ϭ .012. The difference between lyso PtdChol ϩ oleic acid and lyso PtdCho alone, p ϭ .003, and with oleic acid alone, p ϭ .003.
Lipoprotein Effect on Smooth Muscle Cells
Laboratory Investigation • May 2001 • Volume 81 • Number 5 1993). sPLA 2 is present in the media in normal and more so in atherosclerotic arteries specifically colocalizing with VSMC (Hurt-Camejo et al, 1997; Romano et al, 1998) . In the atherosclerotic wall, sPLA 2 was detected both extracellularly in the lipid core, binding avidly to the proteoglycans synthesized by VSMC (Sartipy et al, 1998) , and intracellularly in the macrophages (Hurt-Camejo et al, 1997; Romano et al, 1998) . We found concentrations of sPLA 2 exceeding 50 ng/mg wet weight in the atherosclerotic arterial walls (Pruzanski et al, unpublished) . A specific receptor for sPLA 2 was found in some human tissues (Ancian et al, 1995) and is present on the VSMC (M. Lazdunski, personal communication), but no information is available about the effect of the interaction of extrinsic sPLA 2 with its receptor on the functions of VSMC.
There are no reports regarding the effect of sPLA 2 on proliferation of VSMC. In one study inhibitors of 14 kDa PLA 2 had no effect, whereas inhibitors of 85 kDa PLA 2 inhibited proliferation of VSMC, suggesting that cytosolic PLA 2 -mediated liberation of arachidonic acid is required for cell proliferation (Anderson et al, 1997) . Our study shows that extrinsic secretory gr IIA sPLA 2 per se does not affect the mitogenic activity of VSMC. However, NHDL 3 and especially APHDL 3 hydrolyzed by sPLA 2 , markedly enhance [ 3 H] thymidine incorporation by VSMC. Our study also shows that preincubation of NHDL 3 with SAA increases mitogenic activity of VSMC more than NHDL 3 alone. It does not rule out the possibility that other differences between APHDL 3 and NHDL 3 may also play a role in the enhancement of mitogenic activity of VSMC. Since hydrolysis of lipoproteins by sPLA 2 is associated with marked increase in the lysocompounds and free fatty acids, it is conceivable that the impact of sPLA 2 on VSMC is mediated, in part, through the above hydrolytic products. Indeed, lyso-PtdCho, and linoleic and oleic acids and their combinations markedly increased the mitogenic activity of VSMC. We used conventional concentrations of the above products of hydrolysis of lipoproteins (Bandyopadhyay et al, 1987; Keler et al, 1992; Rao et al 1995; Wang et al 1991) , but their concentrations in the vascular wall are not known presently, and therefore their relative in vivo impact cannot be estimated.
The impact of LDL on mitogenic activity of VSMC was found to vary, depending on experimental conditions (Chen et al, 1986; Fang et al, 1997; Heery et al, 1995; Leitinger et al, 1999; Libby et al, 1985; Locher et al, 1992; Scott-Burden et al, 1989) . Whereas only a minimal effect was reported (Libby et al 1985) , others found that LDL has a definite mitogenic effect (Fang et al, 1997; Locher et al, 1992) . The effect was more pronounced when VSMC were cultured in low-serum medium (Chen et al, 1986) or when LDL was oxidized (Heery et al, 1995) . In our system, LDL induced pronounced mitogenic activity that was further enhanced by extrinsic sPLA 2 . The issue of whether LDL possesses intrinsic PLA 2 activity has not been solved, because no PLA 2 enzyme was extracted from LDL. Studies of the impact of sPLA 2 on LDL have shown that extrinsic sPLA 2 hydrolyzes LDL (Pruzanski et al, 1998) and that sPLA 2 -treated LDL is more efficiently oxidized by cocultures of VSMC with endothelial cells than untreated LDL (Leitinger et al, 1999) .
VSMC also proliferate in response to IL-6 (Gaumond et al, 1997; Loppnow and Libby, 1990; Nabata et al, 1990) , which is induced by PAF (Gaumond et al, 1997) and is synthesized and released from VSMC, especially when the cells are stimulated by IL-1 or PDGF (Loppnow and Libby, 1990) . Activation of IL-6 in VSMC by chlamydial HSP 60 has recently been reported (Kol et al, 1999) .
The impact of enzymes linked to lipoproteins on mitogenesis of VSMC has been investigated only recently. Mitogenic activity of VSMC induced by ox-LDL was blocked by PAF-receptor antagonist (Heery et al, 1995) , and generation of bioactive phospholipids during oxidation of LDL was blocked by PAF-AH (Heery et al, 1995) . Yet, PAF inhibitor, SR 27417, did not inhibit the mitogenic effect of PAF on rabbit VSMC (Herbert et al, 1995) . Another study reported that in LDL PAF-AH mediates conversion of PtdCho into lyso-PtdCho (Steinbrecher and Pritchard, 1989) , a known stimulator of VSMC proliferation. The role of other enzymes such as PON or sphingomyelinase in the induction of mitogenic activity of VSMC has not yet been reported. Our study has shown that human extrinsic gr IIA sPLA 2 markedly enhances the mitogenic activity of lipoproteins and their effect on proliferation of VSMC. Therefore, hydrolysis of lipoproteins that colocalize with sPLA 2 in the arterial wall may enhance the atherosclerotic process. It remains to be seen whether sPLA 2 inhibitors can serve as novel antiatherogenic agents.
Materials and Methods
Blood samples were obtained with informed consent from healthy individuals and from patients in acute phase after cardiac surgery. NHDL 3 and APHDL 3 were isolated by sequential ultracentrifugation as described (Pruzanski et al, 1998) , and purified fractions p 1.13 to 1.18 g/ml were used. Concentration of lipoproteins was expressed in micrograms of protein content. Recombinant human group IIA PLA 2 was kindly provided by Dr. J. Browning, Biogen, Cambridge, Massachusetts. Synthetic recombinant human apo SAA was obtained from Pepro Tech (Rocky Hill, New Jersey). This SAA corresponds to human apo SAA 1␣ with the exception of the N-terminal methionine and substitution of asparagine for aspartic acid at position 60, and was found to be biologically active (Badolato et al, 1994; Su et al, 1999) . NHDL 3 was preincubated with SAA for 4 hours and then added to the cultures of human VSMC as described.
Cell Culture
Human aortal VSMC were obtained from Cascade Biologics (Portland, Oregon) and maintained as recommended by the supplier. VSMC were plated at 4 ϫ Pruzanski et al 10 4 /well. Cells were grown in medium 231 containing smooth muscle cell growth supplement (Cascade Biologics). Only passages 6 and 7 were used for experiments. Before treatment with various agents, VSMC were made quiescent by culturing them for 48 hours (with one medium change after 24 hours) in serum-free medium containing FFA free 0.1% BSA, insulintransferrin-selenium supplement (ITS) (Gibco BRL, Burlington, Ontario, Canada), 0.1 mM vitamin C, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B (P/S). In each experiment, the initial and final cell count were made and LDH concentration was tested in the medium. Microscopic assessment of the size and shape of cells and of detachment was made.
Hydrolysis of Lipoproteins with rh gr IIA PLA 2
Lipoproteins at concentration 1 to 2 mg/ml in 100 mM TrisHCI buffer, pH 8.0, containing 10 mM CaCI2 and 0.2 mg/ml BSA (fatty acid free) were incubated with human recombinant gr II A PLA 2 at concentrations ranging from 0.05 to 5 g/ml, for desired periods of time, at 37°C (Pruzanski et al 1998) . Controls were maintained in identical conditions. 3 H] thymidine 50 Ci/mmol; Amersham, Oakville, Ontario, Canada). After incubation for 24 hours, cells were washed once with 2 ml of ice-cold methanol for 10 minutes, extracted three times with 2 ml of cold 10% TCA for 5 minutes each time, and solubilized for at least 30 minutes at room temperature in 0.25 ml 0.3 N NaOH, 1% SDS. After neutralizing with 0.25 ml 0.3 N HCI, [ 3 H] thymidine activity was measured in a liquid scintillation counter (Beckman LS 7500). Each experiment was performed in triplicate or quadruplicate.
Measurement of DNA Synthesis
In a separate series of experiments (n ϭ 4), the incorporation of [ 3 H] thymidine into VSMC exposed for 24 hours to lipoproteins and to lipoproteins hydrolyzed with sPLA 2 was compared with the number of proliferating cells as described (Heery et al, 1995) (Table 2) .
Agents Tested for Induction of Mitogenic Activity of VSMC
Human VSMC were incubated with various concentrations of unhydrolyzed or sPLA 2 -hydrolyzed NHDL 3 , APHDL 3 , or LDL, or with L-␣-lysophosphatidylcholine, palmitoyl (C 16:0) approximate purity 99%, molecular weight (MW) 495.6; linoleic acid (cis-9, cis-12-octadecadienoic acid) MW 280.4, minimum purity 99%; or oleic acid (cis-9-octadecenoic acid) MW 282.5 approximate purity 99% (Sigma-Aldrich, Oakville, Ontario, Canada). These agents were dissolved in ethanol, using a final nontoxic concentration of 0.1%, which was also used in controls.
Statistical analysis was performed by Student t test, Tukey-Kramer multiple comparison test, and Bartlett's test for homogeneity of variances. [Au: These references were not cited in the text: Jimi et al, 1995; 
